Vandetanib for the Treatment of Medullary Thyroid Carcinoma

Phase II trial of sunitinib in medullary thyroid cancer (MTC).

(2017) J. A. De Souza et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib Plus Chemotherapy for Induction Followed by Vandetanib or Placebo As Maintenance for Patients with Advanced Non–Small-Cell Lung Cancer: A Randomized Phase 2 PrECOG Study (PrE0501)

(2013) Joseph Aisner et al.   Journal of Thoracic Oncology

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole

(2013) Paul Martin et al.   Drugs in research & development

Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary

(2012) K. Thornton et al.   CLINICAL CANCER RESEARCH

Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies

(2012) Justin N. Bottsford-Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics and Tolerability of Vandetanib in Chinese Patients With Solid, Malignant Tumors: An Open-Label, Phase I, Rising Multiple-Dose Study

(2011) Li Zhang et al.   CLINICAL THERAPEUTICS

Pharmacokinetics of Vandetanib: Three Phase I Studies in Healthy Subjects

(2011) Paul Martin et al.   CLINICAL THERAPEUTICS

The Effects of Four Different Tyrosine Kinase Inhibitors on Medullary and Papillary Thyroid Cancer Cells

(2011) Hans H. G. Verbeek et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment

(2010) Angelika Weil et al.   CLINICAL PHARMACOKINETICS

Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

(2010) Bruce G. Robinson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer

(2010) Elaine T. Lam et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

(2010) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer

(2009) Martin J. Schlumberger et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance of SomaticRETOncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study

(2007) Rossella Elisei et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

New therapeutic approaches to treat medullary thyroid carcinoma

(2007) Martin Schlumberger et al.   Nature clinical practice. Endocrinology & metabolism